place

Mainz-Hechtsheim

Boroughs of MainzMainz
Hechtsheim in Mainz
Hechtsheim in Mainz

Hechtsheim is a borough of the Rhineland-Palatinate state capital Mainz, Germany. With an area of 1,404 hectares, it is the largest district in the city.

Excerpt from the Wikipedia article Mainz-Hechtsheim (License: CC BY-SA 3.0, Authors, Images).

Mainz-Hechtsheim
Lindenplatz, Mainz Hechtsheim

Geographical coordinates (GPS) Address Nearby Places
placeShow on map

Wikipedia: Mainz-HechtsheimContinue reading on Wikipedia

Geographical coordinates (GPS)

Latitude Longitude
N 49.960277777778 ° E 8.2802777777778 °
placeShow on map

Address

Lindenplatz 6
55129 Mainz, Hechtsheim
Rhineland-Palatinate, Germany
mapOpen on Google Maps

Hechtsheim in Mainz
Hechtsheim in Mainz
Share experience

Nearby Places

BioNTech
BioNTech

BioNTech SE ( bee-ON-tek; or bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which at the time offered a 91% efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the United Kingdom. It was the first mRNA vaccine ever authorized. Some days later the vaccine also received an emergency approval in the United States, Canada and Switzerland. On 21 December 2020, the European Commission approved BioNTech/Pfizer's coronavirus vaccine in accordance with the positive recommendation of the European Medicines Agency (EMA).